CONTENTS

ACCELERATED COMMUNICATIONS

TOM M. STORMANN, DAVID C. GDULA, DAVID M. WEINER, AND MARK R. BRANN. Molecular Cloning and Expression of a Dopamine D2 Receptor from Human Retina .......................... 1
JENNY HENKEL-TIGGES AND RONALD L. DAVIS. Rat Homologs of the Drosophila dunce Gene Code for Cyclic AMP Phosphodiesterases Sensitive to Rolipram and RO 20-1724 ........ 7

ARTICLES

PAOLA DE ISABELLA, GIOVANNI CAPRANICO, MONICA BINASCHI, STELLA TINELLI, AND FRANCO ZUNINO. Evidence of DNA Topoisomerase II-Dependent Mechanisms of Multidrug Resistance in P388 Leukemia Cells .................................................. 11
GANG WANG, MARTIN DUGAS, I. BEN ARMAH, AND PETER HONERJAGER. Interaction between DPI 201-106 Enantiomers at the Cardiac Sodium Channel .................................... 17
TIAN-JUN HUANG AND MAHIN D. MAINES. Bromobenzene-Mediated Alteration in Activity and Electrophoretic Pattern of Biliverdin Reductase Variants in Rat Kidney .......... 25
TOSHI NAKAKI, MISA NAKAYAMA, SATOSHI YAMAMOTO, AND RYUICHI KATO. α-Aldrenergic Stimulation and β2-Adrenergic Inhibition of DNA Synthesis in Vascular Smooth Muscle Cells .............................................. 30
DOMINIC J. ROCA, INNA ROZENBERG, MARK FARRANT, AND DAVID H. FARBE. Chronic Agonist Exposure Induces Down-regulation and Allosteric Uncoupling of the γ-Aminobutyric Acid/Benzodiazepine Receptor Complex .................................................. 37
JEFFREY R. JASPER, MARTIN C. MICHEL, AND PAUL A. INSEL. Amplification of Cyclic AMP Generation Reveals Agonistic Effects of Certain β-Adrenergic Antagonists .... 44
JEAN M. BIDLACK, DAVID K. FREY, RICHARD A. KAPLAN, AHMAD SEYED-MOZAFFARI, AND SYDNEY ARCHER. Affinity Labeling of μ Opioid Receptors by Sulphydryl Alkylating Derivatives of Morphine and Morphinone ............................................. 50
SEYMOUR MONG AND HENRY M. SARAU. Post Soluble Binding to the Leukotriene D4 Receptor from Guinea Pig Lung Membranes ......................................................... 60
MARTIN C. MICHEL, JOHN W. REGAN, MARK A. GERHARDT, RICHARD R. NEUBIG, PAUL A. INSEL, AND HARVEY J. MOTULSKY. Nonadrenergic [3H]Idazoxan Binding Sites Are Physically Distinct from α2-Adrenergic Receptors ........................................ 65
ANTONIO LAURENZZA, DIANE MORRIS, AND KENNETH B. SEAMON. Irreversible Loss of [3H]Forskolin Binding Sites in Human Platelets by α-Haloacetyl Analogs of Forskolin .... 69
HOAU-YAN WANG AND EITAN FREIDMAN. Central 5-Hydroxytryptamine Receptor-Linked Protein Kinase C Translocation: A Functional Postsynaptic Signal Transduction System .................................................. 75
WILLIAM P. SCHILLING, MONA C. ZAHER, AND DAVID RAMPE. Effect of Inorganic Calcium Channel Blockers on Dihydropyridine Binding to Cardiac Sarcolemma ........ 80
M. QUIK, R. AFAR, S. GEERTSEN, T. AUDHYA, G. GOLSTEIN, AND J.-M. TRIFARO. Thymopoietin, a Thymic Polypeptide, Regulates Nicotinic α-Bungarotoxin Sites in Chromaffin Cells in Culture .................................................. 90
KATHERINE D. HOLLAND, DEAN K. NARITOKU, ANN C. McKEON, JAMES A. FERRENDELLI, AND DOUGLAS F. COVEY. Convulsant and Anticonvulsant Cyclopentanones and Cyclohexanones ............................................... 98
HITOSHI HOUCHI, JOSEPH M. MASSERANO, JOHN F. BOWYER, AND NORMAN WEINER. Regulation of Tyrosine Hydroxylase Activity in Pheochromocytoma PC-12 Cells by Bradykinin .................................................. 104

Continued
CONTENTS (cont’d)

BRUCE G. JENKINS AND RANDALL B. LAUFFER. Detection of Site-Specific Binding and Co-binding of Ligands to Human Serum Albumin using 39F NMR ........................................ 111

KENNETH E. THUMMEL AND JOHN B. SCHEMKAN. Effects of Testosterone and Growth Hormone Treatment on Hepatic Microsomal P450 Expression in the Diabetic Rat ... 119

D. S. RIDDICK, S. S. PARK, H. V. GELBOIN, AND G. S. MARKS. Effects of 4-Alkyl Analogues of 3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on Hepatic Cytochrome P-450 Heme, Apoproteins, and Catalytic Activities following In Vivo Administration to Rats .................................................. 130